EE04996B1 - Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend - Google Patents
Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakendInfo
- Publication number
- EE04996B1 EE04996B1 EEP200100319A EEP200100319A EE04996B1 EE 04996 B1 EE04996 B1 EE 04996B1 EE P200100319 A EEP200100319 A EE P200100319A EE P200100319 A EEP200100319 A EE P200100319A EE 04996 B1 EE04996 B1 EE 04996B1
- Authority
- EE
- Estonia
- Prior art keywords
- preparation
- dosage form
- controlled release
- pharmaceutical packaging
- galantamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98204447 | 1998-12-24 | ||
PCT/EP1999/010257 WO2000038686A1 (en) | 1998-12-24 | 1999-12-20 | Controlled release galantamine composition |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200100319A EE200100319A (et) | 2002-10-15 |
EE04996B1 true EE04996B1 (et) | 2008-04-15 |
Family
ID=8234559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200100319A EE04996B1 (et) | 1998-12-24 | 1999-12-20 | Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend |
Country Status (36)
Country | Link |
---|---|
US (3) | US7160559B1 (zh) |
EP (1) | EP1140105B1 (zh) |
JP (1) | JP2002533396A (zh) |
KR (1) | KR100437105B1 (zh) |
CN (1) | CN100370990C (zh) |
AP (1) | AP1414A (zh) |
AR (2) | AR022008A1 (zh) |
AT (1) | ATE252386T1 (zh) |
AU (1) | AU775914B2 (zh) |
BG (1) | BG65306B1 (zh) |
BR (1) | BR9916835A (zh) |
CA (1) | CA2358062C (zh) |
CZ (1) | CZ301658B6 (zh) |
DE (1) | DE69912311T2 (zh) |
DK (1) | DK1140105T3 (zh) |
EA (1) | EA004936B1 (zh) |
EE (1) | EE04996B1 (zh) |
ES (1) | ES2211215T3 (zh) |
HK (1) | HK1043062A1 (zh) |
HR (1) | HRP20010463B1 (zh) |
HU (1) | HUP0104778A3 (zh) |
ID (1) | ID29021A (zh) |
IL (2) | IL143899A0 (zh) |
MY (1) | MY122411A (zh) |
NO (1) | NO327988B1 (zh) |
NZ (1) | NZ511643A (zh) |
OA (1) | OA11740A (zh) |
PL (1) | PL349501A1 (zh) |
PT (1) | PT1140105E (zh) |
SI (1) | SI1140105T1 (zh) |
SK (1) | SK287676B6 (zh) |
TR (1) | TR200101822T2 (zh) |
TW (1) | TWI262079B (zh) |
UA (1) | UA79578C2 (zh) |
WO (1) | WO2000038686A1 (zh) |
ZA (1) | ZA200105132B (zh) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5558648B2 (ja) | 1998-11-23 | 2014-07-23 | デイビス、ボニー | アセチルコリンエステラーゼ阻害剤のための投与製剤 |
HUP0104778A3 (en) | 1998-12-24 | 2004-05-28 | Janssen Pharmaceutica Nv | Controlled release galantamine composition |
CA2310926C (en) * | 2000-04-03 | 2002-10-15 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
DE10134038A1 (de) * | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
AU2002340232A1 (en) * | 2001-10-17 | 2003-04-28 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
DE10235556A1 (de) * | 2002-08-03 | 2004-02-19 | Hf Arzneimittelforschung Gmbh | Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums |
SI1578422T1 (sl) | 2002-12-20 | 2007-12-31 | Niconovum Ab | Fizikalno in kemiäśno stabilni nikotin in mikrokristal na celulozo vsebujoäś material iz trdnih delcev |
ITMI20030827A1 (it) * | 2003-04-18 | 2004-10-19 | Unihart Corp | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. |
US7250258B2 (en) | 2003-12-15 | 2007-07-31 | Pgxhealth Llc | CDK5 genetic markers associated with galantamine response |
WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
EP2340813A1 (en) * | 2003-12-31 | 2011-07-06 | Actavis Group PTC ehf. | Solid dosage formulations of galantamine |
CA2552114A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
GB0408308D0 (en) * | 2004-04-14 | 2004-05-19 | Vectura Ltd | Pharmaceutical compositions |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
EP1830886B1 (en) * | 2004-12-27 | 2016-04-13 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
JP5597343B2 (ja) * | 2005-04-28 | 2014-10-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬を含有する組成物 |
US20090087488A1 (en) * | 2005-09-05 | 2009-04-02 | Rajan Kumar Verma | Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use of the manufacture of a medicament |
US20070092568A1 (en) * | 2005-10-10 | 2007-04-26 | Gore Subhash P | Galantamine compositions |
WO2007104573A2 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
HUE029173T2 (hu) * | 2006-04-26 | 2017-02-28 | Alphapharm Pty Ltd | Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot |
WO2008062426A2 (en) * | 2006-08-02 | 2008-05-29 | Emcure Pharmaceuticals Limited | Formulation of benzazepine derivatives |
US7955622B2 (en) | 2006-10-13 | 2011-06-07 | Actavis Group Ptc Hf | Controlled-release galantamine formulations |
DE102006056697A1 (de) * | 2006-11-30 | 2008-06-05 | Ratiopharm Gmbh | Galanthamin-haltiges Arzneimittel mit kontrollierter Freisetzung |
NZ599031A (en) * | 2007-02-09 | 2013-11-29 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
KR100782310B1 (ko) | 2007-03-22 | 2007-12-06 | 현대약품 주식회사 | 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물 |
US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
WO2009024858A1 (en) * | 2007-08-22 | 2009-02-26 | Aurobindo Pharma Limited | Controlled release dosage form of galantamine |
EP2190419A1 (en) * | 2007-10-05 | 2010-06-02 | KRKA, D.D., Novo Mesto | Multi particulate matrix system containing galantamine |
EP2044933A1 (en) * | 2007-10-05 | 2009-04-08 | KRKA, D.D., Novo Mesto | Multi particulate matrix system containing galantamine |
CA2615137A1 (en) * | 2007-12-17 | 2009-06-17 | Pharmascience Inc. | Single layered controlled release therapeutic system |
EP2116232B1 (de) | 2008-05-09 | 2012-02-15 | Ratiopharm GmbH | Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
EP2503996A2 (en) | 2009-11-26 | 2012-10-03 | USV Limited | Controlled release pharmaceutical compositions of galantamine |
WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
GR1007767B (el) | 2011-07-26 | 2012-11-19 | Φαρματεν Αβεε, | Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου |
WO2014066318A1 (en) | 2012-10-25 | 2014-05-01 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
EP3033082B1 (en) | 2013-08-16 | 2021-06-16 | Universiteit Maastricht | Treatment of cognitive impairment with pde4 inhibitor |
JP2016534063A (ja) | 2013-10-22 | 2016-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリン誘導体ならびに関連するイメージングおよび治療方法 |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
EP3506894B1 (en) | 2016-08-31 | 2023-08-23 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
GB201620095D0 (en) | 2016-11-28 | 2017-01-11 | Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And | Novel use |
CN115715769A (zh) * | 2017-05-19 | 2023-02-28 | 比斯坎神经治疗公司 | 石杉碱的改良释放药物组合物以及其使用方法 |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
WO2019017995A1 (en) | 2017-07-20 | 2019-01-24 | Aztherapies, Inc. | FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN |
US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
KR20210071943A (ko) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
BG67408B1 (bg) | 2019-04-12 | 2022-01-17 | Софарма Ад | Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE450087B (sv) * | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
AU632458B2 (en) | 1987-05-04 | 1993-01-07 | Bonnie Davis | Compounds for the treatment of alzheimer's disease |
CA1326632C (en) * | 1988-10-26 | 1994-02-01 | Bonnie Davis | Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease |
US5085865A (en) * | 1989-04-12 | 1992-02-04 | Warner-Lambert Company | Sustained release pharmaceutical preparations containing an analgesic and a decongestant |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
US5519017A (en) | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
AT397345B (de) | 1990-04-04 | 1994-03-25 | Chemiefaser Lenzing Ag | Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen |
JP2542122B2 (ja) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
US5336675A (en) | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
US5312817A (en) * | 1991-05-14 | 1994-05-17 | Ernir Snorrason | Treatment of fatigue syndrome |
US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
US5229135A (en) * | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
DE4301782C1 (de) | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
DE4301783C1 (de) * | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
JPH08511257A (ja) * | 1993-06-14 | 1996-11-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アステミゾールとプソイドエフェドリンの長期放出型フィルムコーティング錠剤 |
DE4319760A1 (de) * | 1993-06-15 | 1994-12-22 | Bayer Ag | Ipsapiron Arzneimittelzubereitung |
WO1995003052A1 (en) * | 1993-07-22 | 1995-02-02 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
EP0647448A1 (en) * | 1993-10-07 | 1995-04-12 | Euroceltique S.A. | Orally administrable opioid formulations having extended duration of effect |
US6323196B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
US6323195B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
DE4342174C1 (de) * | 1993-12-10 | 1995-05-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung |
US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
GB9514821D0 (en) | 1995-07-19 | 1995-09-20 | Sod Conseils Rech Applic | Galanthamine derivatives |
JP3833314B2 (ja) * | 1995-09-08 | 2006-10-11 | 武田薬品工業株式会社 | 発泡性組成物およびその製造方法 |
JP3693270B2 (ja) * | 1995-10-12 | 2005-09-07 | 旭化成ケミカルズ株式会社 | フィルムコーティング顆粒およびその製造方法 |
SE9504537D0 (sv) * | 1995-12-19 | 1995-12-19 | Jan Hedner | Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet |
JP3134187B2 (ja) * | 1996-03-07 | 2001-02-13 | 武田薬品工業株式会社 | 放出制御組成物 |
TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
CA2272099A1 (en) * | 1996-11-19 | 1998-05-28 | The Procter & Gamble Company | Compliance package and method of improving or aiding patient compliance for complex drug regimens |
JPH10231242A (ja) * | 1997-02-20 | 1998-09-02 | Taiyo Yakuhin Kogyo Kk | 持続性ジクロフェナクナトリウム組成物 |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
TW477702B (en) * | 1997-10-23 | 2002-03-01 | Dev Center Biotechnology | Controlled release tacrine dosage form |
AU1282099A (en) | 1997-10-29 | 1999-05-17 | Bonnie M. Davis | Method for treatment of disorders of attention |
JP5558648B2 (ja) | 1998-11-23 | 2014-07-23 | デイビス、ボニー | アセチルコリンエステラーゼ阻害剤のための投与製剤 |
HUP0104778A3 (en) * | 1998-12-24 | 2004-05-28 | Janssen Pharmaceutica Nv | Controlled release galantamine composition |
AUPP891299A0 (en) | 1999-02-26 | 1999-03-25 | Fujisawa Pharmaceutical Co., Ltd. | New 6-membered cyclic compounds |
US6273260B1 (en) * | 2000-03-08 | 2001-08-14 | Eli Lilly And Company | Pharmaceutical packaging system |
-
1999
- 1999-12-20 HU HU0104778A patent/HUP0104778A3/hu unknown
- 1999-12-20 EA EA200100713A patent/EA004936B1/ru not_active IP Right Cessation
- 1999-12-20 EE EEP200100319A patent/EE04996B1/xx unknown
- 1999-12-20 SI SI9930484T patent/SI1140105T1/xx unknown
- 1999-12-20 CN CNB998149888A patent/CN100370990C/zh not_active Expired - Lifetime
- 1999-12-20 WO PCT/EP1999/010257 patent/WO2000038686A1/en active IP Right Grant
- 1999-12-20 PT PT99965527T patent/PT1140105E/pt unknown
- 1999-12-20 KR KR10-2001-7006141A patent/KR100437105B1/ko active IP Right Grant
- 1999-12-20 JP JP2000590639A patent/JP2002533396A/ja active Pending
- 1999-12-20 US US09/868,991 patent/US7160559B1/en not_active Expired - Lifetime
- 1999-12-20 NZ NZ511643A patent/NZ511643A/en not_active IP Right Cessation
- 1999-12-20 UA UA2001064400A patent/UA79578C2/uk unknown
- 1999-12-20 SK SK886-2001A patent/SK287676B6/sk not_active IP Right Cessation
- 1999-12-20 EP EP99965527A patent/EP1140105B1/en not_active Expired - Lifetime
- 1999-12-20 AT AT99965527T patent/ATE252386T1/de active
- 1999-12-20 PL PL99349501A patent/PL349501A1/xx not_active Application Discontinuation
- 1999-12-20 IL IL14389999A patent/IL143899A0/xx active IP Right Grant
- 1999-12-20 CA CA002358062A patent/CA2358062C/en not_active Expired - Lifetime
- 1999-12-20 ID IDW00200101372A patent/ID29021A/id unknown
- 1999-12-20 DE DE69912311T patent/DE69912311T2/de not_active Expired - Lifetime
- 1999-12-20 TR TR2001/01822T patent/TR200101822T2/xx unknown
- 1999-12-20 OA OA1200100170A patent/OA11740A/en unknown
- 1999-12-20 ES ES99965527T patent/ES2211215T3/es not_active Expired - Lifetime
- 1999-12-20 CZ CZ20012182A patent/CZ301658B6/cs not_active IP Right Cessation
- 1999-12-20 AU AU21006/00A patent/AU775914B2/en not_active Expired
- 1999-12-20 DK DK99965527T patent/DK1140105T3/da active
- 1999-12-20 AP APAP/P/2001/002219A patent/AP1414A/en active
- 1999-12-20 BR BR9916835-9A patent/BR9916835A/pt not_active Application Discontinuation
- 1999-12-23 TW TW088122698A patent/TWI262079B/zh not_active IP Right Cessation
- 1999-12-23 MY MYPI99005716A patent/MY122411A/en unknown
- 1999-12-23 AR ARP990106725A patent/AR022008A1/es not_active Application Discontinuation
-
2001
- 2001-06-05 BG BG105564A patent/BG65306B1/bg unknown
- 2001-06-08 NO NO20012857A patent/NO327988B1/no not_active IP Right Cessation
- 2001-06-19 HR HR20010463A patent/HRP20010463B1/xx not_active IP Right Cessation
- 2001-06-21 ZA ZA200105132A patent/ZA200105132B/en unknown
- 2001-06-21 IL IL143899A patent/IL143899A/en not_active IP Right Cessation
-
2002
- 2002-07-02 HK HK02104948A patent/HK1043062A1/xx not_active IP Right Cessation
-
2005
- 2005-10-31 US US11/262,668 patent/US20060062856A1/en not_active Abandoned
- 2005-12-15 US US11/304,128 patent/US20060093671A1/en not_active Abandoned
-
2008
- 2008-04-25 AR ARP080101771A patent/AR066313A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE04996B1 (et) | Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend | |
EE03902B1 (et) | Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend | |
EE05232B1 (et) | Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm | |
LTPA2014005I1 (lt) | Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas | |
EE05086B1 (et) | Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus | |
EE04991B1 (et) | Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend | |
PL396568A1 (pl) | Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny | |
EE9800383A (et) | Meetod bioloogiliselt sobivate biodegradeeruvate mikroosakeste valmistamiseks, mikroosakesed ja nendest koosnev materjal, farmatseutiline kompositsioon ning mikroosakeste kasutamine | |
EE9700328A (et) | Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine | |
HUP0200309A3 (en) | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them | |
IS5747A (is) | Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær | |
EE04417B1 (et) | Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine | |
EE03552B1 (et) | Tahke doseerimisvorm, selle valmistamismeetod, seda sisaldav produkt, tablett ja farmatseutiline pakend ning tsisapriidisoolade kasutamine | |
EE05214B1 (et) | Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon | |
ZA200110217B (en) | Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application. | |
AU6275601A (en) | Stable polymeric micelle-type drug composition and method for the preparation thereof | |
EE05506B1 (et) | Ravimi manustamise vahend eriti progestiinide jastrogeenide manustamiseks | |
EE200300207A (et) | Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon | |
PL333524A1 (en) | Improved prolonged release pharmaceutic preparation for administration of nephadosone, oral dosage form thereof and improved nephadosone administration method | |
EE05242B1 (et) | 5-kloro-3-(4-metaansulfonlfenl)-6'-metl[2,3']bipridinli polmorfne vorm, selle valmistamismeetod, kasutamine ja farmatseutiline kompositsioon | |
EE200300153A (et) | Östrogeeni retseptori modulaatorid, farmatseutiline kompositsioon ja selle valmistamismeetod | |
EE9900162A (et) | Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine | |
EE200200199A (et) | N-guanidinoalküülamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine | |
EE9800075A (et) | Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks | |
EE04718B1 (et) | PDE IV inhibeerivad püridiini derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon ja selle valmistamismeetod |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |